Skip to content

How to Read an NIH Summary Statement: Scores and Critiques

Grantsights17 min readLast updated October 2026

Quick Answer: Your NIH summary statement arrives in eRA Commons after your study section meets.

In this guide (12 sections)

Get deadline alerts for these grants

Enter your email for a weekly email of upcoming grant deadlines.

No spam. A weekly email with upcoming grant deadlines.

Full answer: Your NIH summary statement arrives in eRA Commons after your study section meets. It contains the written critiques from the three assigned reviewers and, if your application was discussed, an overall impact score (10-90) and usually a percentile. Under NOT-OD-26-114, most meetings through the January 2027 council discuss only 30-35% of applications, so many strong applications now come back "competitive but not discussed." This guide is for principal investigators, postdocs, research administrators, and grant teams deciding whether to resubmit, revise aims, talk to a program officer, or move to another mechanism. Focus first on the score-driving points and criterion or factor scores, then read the critiques strategically for resubmission planning.

How to Read Your NIH Summary Statement (2026 Guide)

Data note: Award amounts and success rates are based on the most recent federal fiscal year data (FY2024-2025) from agency databases and USASpending.gov. Program parameters may change with annual appropriations.

If you've submitted an NIH grant application, the summary statement is the most important document you'll receive from the peer review process. It contains your priority score, your criterion scores, your percentile rank, and the full written critiques from every assigned reviewer.

If you're a principal investigator, postdoc preparing for resubmission, or research administrator interpreting peer review feedback, this guide breaks down every section of an NIH summary statement.

Most applicants know what a summary statement is. Fewer know how to read one strategically. This guide explains how to read your NIH summary statement, decode the language reviewers use, and turn the feedback into a stronger resubmission.

Last updated: October 2026


Grantsights Source Review and Decision Evidence

Source review by Grantsights: we checked NIH peer review scoring guidance, NIH scoring system details, eRA Commons guidance, NIH resubmission guidance, NIH paylines and funding strategy pages, RePORTER before this update. The practical gap is that NIH explains scoring mechanics, but applicants need a practical decision path for whether the summary statement supports resubmission, a new application, or a program officer discussion.

Source checkedWhat it provesApplicant action
NIH peer review guidanceOverall impact, criterion scores, and discussion status have different meaningsDo not average criterion scores to predict funding
NIH scoring systemThe 10-90 score derives from reviewer impact ratingsUse the score with percentile and institute context
eRA CommonsThe summary statement is accessed through application statusPull the official document before interpreting secondhand notes
NIH resubmission guidanceA1 applications must respond to prior reviewBuild the introduction from actual critique themes
RePORTER and institute funding pagesAward history and paylines vary by institute and mechanismCompare your score to institute strategy before deciding

According to NIH, the overall impact score uses a 10-90 scale based on reviewer impact ratings. According to eRA Commons, applicants access official application status and documents through eRA systems. According to NIH resubmission guidance, resubmissions need a direct response to prior review. According to NIH RePORTER, funded-project history can help interpret whether a topic and institute are realistic.

Decision checklist: confirm discussed status, overall impact score, percentile, criterion pattern, repeated critique themes, institute payline, program officer signal, and resubmission deadline before rewriting. A common mistake is treating every critique equally or rewriting the whole application without identifying the score-driving weakness. For example, one application with strong significance but weak approach may need design and rigor changes, while a not-discussed application with broad premise concerns may need a new strategy.

What Official Sources Don't Tell You

Official NIH pages define the review process, but they do not always show how to triage reviewer comments by decision value. The practical gap is resubmission judgment: applicants should separate fatal concerns, fixable execution issues, and reviewer preferences before spending months on an A1.

Use the Grantsights database to compare NIH opportunities and related mechanisms, then see pricing for Grantsights Pro, which includes the full match plan.

What the NIH Summary Statement Is

The summary statement is NIH's compiled record of everything that happened during peer review of your application. It includes:

  • The overall impact score
  • Criterion or factor scores from the assigned reviewers
  • Percentile rank (for most mechanisms and institutes)
  • Full written critiques from each assigned reviewer
  • A short summary of the committee outcome (under the 2026 format, a sentence on the level of agreement plus bullet points on the main scoring factors)

It's your primary feedback document, regardless of outcome. Whether your application was funded, scored but not funded, or triaged without discussion, the summary statement tells you precisely what the study section thought of your science and your approach.

When does it arrive? Some weeks after the study section meeting, which itself happens roughly 4 to 5 months after your submission deadline. eRA Commons notifies you when it posts. You access it through eRA Commons: log in, work through to your application, and find the summary statement in the application status section.


The Structure of an NIH Summary Statement

Understanding the structure before you read will help you work through the document instead of getting lost in it.

Section 1: Cover Sheet

Basic identifying information - your name, application title, study section name and chair, meeting date, and the reviewers assigned to your application. You won't learn anything here you don't already know, but it's worth verifying the study section that reviewed your application was appropriate for your science.

Section 2: Overall Impact Score

This is the number most applicants look at first. The scale runs from 10 (best) to 90 (worst). Discussed applications get final impact ratings (1 to 9) from all eligible study section members without a conflict, not just the assigned reviewers. According to the NIH scoring system and procedure, those ratings are averaged and multiplied by 10.

There's a common misconception worth correcting here: the overall impact score is not an average of the criterion scores. Reviewers are explicitly asked to give a whole-person judgment of the application's potential impact on the field, independent of how they scored individual criteria. A poor score on one factor doesn't automatically produce a poor overall impact score if the reviewers believe the science is fundamentally important and the problems are addressable.

If your application wasn't discussed: You'll see "ND" (Not Discussed) instead of a numeric score. Historically about half of applications were discussed. NOT-OD-26-114 (September 8, 2026) says most meetings through the January 2027 Advisory Council will discuss 30-35% instead. The middle third of applications are labeled "competitive but not discussed" and are still considered for funding alongside discussed applications; the lowest third are "not competitive and not discussed." Check which label you got. You still receive the written critiques from the assigned reviewers. We'll cover what to do with a not-discussed application below.

Section 3: Percentile Rank

Your percentile rank is where your application falls relative to all applications reviewed by the same study section over the preceding year (3 sequential meetings). The scale runs from 1 to 99, where 1 is the most competitive position (top 1% of applications).

This is what NIH institutes actually use to set funding decisions. Most institutes establish a "payline" - a percentile cutoff below which applications are funded. If your application scores at the 8th percentile and the payline is the 10th percentile, you're in the fundable range. If it's at the 14th percentile, you're above the payline and unlikely to be funded in that cycle without a special program officer pick-up.

Some mechanisms and institutes don't produce percentile ranks. If you're unclear about whether your application was percentiled, contact the institute's grants management officer.

Section 4: Criterion Scores

For due dates on or after January 25, 2025, NIH moved most research project grants from the old 5-criterion framework to a new 3-factor framework under NOT-OD-24-010. It applies to listed activity codes such as R01, R03, R15, R21, R33, R34, U01 and the DP series. K, F, T and P applications aren't covered and still use their own criteria. For NIH's full overview of the peer review process, see the NIH Peer Review page.

The old framework (before January 25, 2025) used 5 criteria:

  1. Significance
  2. Innovation
  3. Approach
  4. Investigators
  5. Environment

The new framework (research project grants) uses 3 factors:

  • Factor 1 - Importance of the Research: Combines the old Significance and Innovation criteria. Scored 1 to 9.
  • Factor 2 - Rigor and Feasibility: Corresponds to the old Approach criterion, including clinical trial-specific components. Scored 1 to 9.
  • Factor 3 - Expertise and Resources: Corresponds to the old Investigators and Environment criteria. This factor isn't scored. Reviewers pick "Appropriate" or "Identify need for additional expertise and/or resources," and the second choice requires a short explanation of the gap.

The change to Factor 3 is deliberate. Under the old system, investigator reputation and institutional prestige (or lack of it) directly influenced the numeric score. Taking it out of the numeric scoring is meant to reduce some of the built-in bias that advantaged applicants at well-resourced institutions with well-known PIs.

Sections 5 Through 7: Individual Reviewer Critiques

This is where most of your useful information lives. Each assigned reviewer writes a separate critique. You'll see them labeled "Reviewer 1," "Reviewer 2," "Reviewer 3." Under NOT-OD-26-114, all summary statements include the three assigned reviewers' critiques, but the narrative paragraph summarizing committee discussion has been dropped in favor of a sentence on the level of agreement and bullet points on the main scoring factors. The identity of reviewers is anonymous.

Each reviewer's critique covers each criterion or factor with labeled "Strengths" and "Weaknesses" sections, plus an overall narrative. The table shows both scoring setups.

Score ElementApplies ToScore Range
Overall ImpactAll discussed applications10 (high) to 90 (low)
Factor 1: Importance of the ResearchResearch project grants (NOT-OD-24-010)1 (exceptional) to 9 (poor)
Factor 2: Rigor and FeasibilityResearch project grants1 to 9
Factor 3: Expertise and ResourcesResearch project grantsAppropriate, or need identified (no number)
Significance, Investigator(s), Innovation, Approach, EnvironmentK, F, T, P and other mechanisms outside NOT-OD-24-0101 to 9 each

How to Decode Critique Language

Reviewer critiques use a specific vocabulary that signals how seriously each concern should be weighted. Learning this vocabulary changes how you read the document.

"The reviewers were concerned that..." This phrasing signals that the concern was raised in the full panel discussion - not just by one assigned reviewer. Panel consensus carries more weight than a single reviewer's opinion.

"Reviewer 1 raised a concern..." (without the "the reviewers" prefix) This is a minority view from one assigned reviewer, not necessarily panel consensus. It still needs to be addressed in a resubmission, but it may not be what drove the score down.

"Major concern" This is serious. A major concern identifies something that fundamentally undermines the application's merit in that reviewer's view. If multiple reviewers flag the same major concern, it almost certainly drove the overall impact score down. You must address major concerns in any resubmission.

"Weakness" A problem that reduces the score but doesn't disqualify the application. Weaknesses should be addressed in resubmission but don't require the same level of remediation as major concerns.

"Minor concern" or "suggestion" Usually optional to address. These are points where a reviewer thought something could be improved or clarified but didn't consider it central to the application's merit. Use your 1-page introduction strategically - don't spend half of it on minor comments.

Past tense phrasing ("the reviewers noted," "the panel discussed") Signals that this item was raised in the study section discussion, not just in the pre-meeting written review.

When Reviewers Disagree with Each Other

It's common to find that Reviewer 1 rates Factor 2 (Rigor and Feasibility) at 2 (outstanding) while Reviewer 3 rates it at 7 (fair). Don't panic, and don't try to argue that one reviewer was right and the other wrong.

The disagreement usually means one reviewer has domain expertise in the specific methodology you're using and the other doesn't. Your resubmission should address the substance of the concern, not the disagreement itself. If Reviewer 3's concern is methodologically valid, engage with it seriously even if Reviewer 1 didn't share it.


From Manusights, our sister product

Once you've decoded the critiques, the hard part is deciding which ones to answer, and how.

Manusights offers an AI critique of NIH applications against NIH's review criteria. For a resubmission, you upload your summary statement and your application. Each critique is sorted into “the reviewers missed it”, “we were unclear” or “a real flaw”, and the fixes are ranked by the criterion each one moves. Writing a new F31, F32, R01 or R21? It critiques those before you submit, too.

It's critique only. It never writes any part of your application, gives no score, and doesn't predict whether you'll be funded. NIH has no part in it.

Order online: $49 for an F31 or F32, $149 for a new R01, R21 or K award application, $199 for a resubmission plan. Back within 3 business days of your upload.

Order a grant review

What to Do if Your Application Was Triaged

Triage doesn't mean your science is bad. It means your application didn't stand out sufficiently from the competitive pool in that cycle. With only 30-35% discussed at most 2026 meetings, a "competitive but not discussed" label means your application is still considered for funding, so talk to your program officer before deciding anything. Here's what actually happens:

  • You receive written critiques from the three assigned reviewers, even though the application wasn't brought to the full panel for discussion
  • You don't receive an overall impact score or a percentile rank
  • The critiques may be shorter and less detailed than critiques for discussed applications, because there was no panel discussion to synthesize

What not to do: Don't assume triage means your project is fundamentally flawed. A not-discussed A0 can still become a funded A1 when the critiques point to fixable problems.

What to do:

  1. Read the critiques carefully and identify whether the concerns are addressable
  2. Call your program officer and ask whether a resubmission is worth pursuing given the current funding climate at that institute
  3. Assess whether the scientific approach itself needs to change or whether the application needs clearer presentation and stronger preliminary data

Your program officer can tell you how your application compared to others in that study section cycle - not numerically, but in qualitative terms. That conversation is worth having before you commit to a resubmission.


Using the Summary Statement to Build Your Resubmission

NIH allows one resubmission (called an A1). The resubmission includes a 1-page "Introduction to Revised Application" at the beginning of the research strategy. That 1 page is your entire formal response to the reviewers.

Priority framework for the introduction:

  1. Address major concerns first - these likely drove the score and must be resolved
  2. Address weaknesses raised by multiple reviewers second - even if each reviewer called it minor, convergence signals it matters
  3. Address single-reviewer minor concerns briefly, or fold them into revisions without calling them out explicitly
  4. Note any major additions (new preliminary data, new collaborators, new methodology) that strengthen the application independent of reviewer comments

What good resubmission language looks like:

"We agree with the reviewers' concern that the preliminary data supporting Aim 2 was insufficient. We have conducted [specific experiments] since the original submission, and the results (summarized in Figure 3, Research Strategy pages 8-9) now provide direct evidence that [specific finding]. The Research Strategy has been revised to clarify the mechanistic rationale for Aim 2 throughout."

Notice what this does: it acknowledges the concern without being defensive, states specifically what was done, points the reviewer to where the evidence is, and explains how the revision addresses the underlying issue.

What weak resubmission language looks like:

"We have addressed all reviewer concerns."

This tells the reviewer nothing and signals you haven't engaged seriously with the feedback.

A note on new reviewers: The resubmission panel may include entirely different people than the original panel. Write your introduction so that it makes sense to someone who didn't read the original application. Don't assume the new reviewers know what Reviewer 1 originally said.

Use formatting to signal changes: Italics or a different font style on revised text in the research narrative lets reviewers quickly locate the changes you're describing in the introduction. Every change you mention in the introduction should be findable in the revised narrative.


What to Ask Your Program Officer After Receiving Your Summary Statement

You can and should contact your program officer after receiving your summary statement. They can't tell you how to write your application, but they can tell you things the summary statement doesn't.

Questions worth asking:

  • "My application scored at the [X]th percentile. What is your institute's current payline for this mechanism?"
  • "Given the current funding climate, is a resubmission of this application worth pursuing?"
  • "Which of the reviewer concerns, in your reading, were most central to the score?"
  • "Are there programmatic priorities at [institute] I should factor into a resubmission?"

Don't ask your program officer to review a draft of your resubmission - they can't do that. Do ask them to help you understand whether a resubmission is a realistic path to funding.

For a deeper look at the resubmission process itself, see How to Respond to Grant Reviewer Comments.


NIH Paylines by Institute (FY2025 Context)

Paylines change from year to year based on appropriations and portfolio priorities, and several institutes no longer publish a fixed cutoff. NCI, for example, says on its peer review and funding outcomes page that it "does not establish an absolute payline" and follows the NIH Unified Funding Strategy. Check the specific institute's current funding policy page, and ask your program officer, before drawing conclusions about your application's competitiveness.

Institutes that do publish funding guidance often give Early Stage Investigators more room than established investigators. If you qualify as an ESI (within 10 years of completing your terminal degree and haven't previously held a major independent research award), confirm that designation in eRA Commons before submission. It can be the difference between funded and not funded.

For historical data on R01 success rates and percentile trends by institute, see NIH R01 Grant Success Rate Data.


What the New Three-Factor Framework Actually Changed in Review Outcomes

The change to Factor 3 in the January 25, 2025 transition to the Simplified Peer Review Framework is more consequential than most applicants realize. Under the old system, Investigators and Environment were scored numerically, which meant a PI at a large R1 university with NIH-funded lab space received a structural score advantage over an equally capable PI at a smaller institution. Factor 3 is no longer scored: reviewers pick "Appropriate" or "Identify need for additional expertise and/or resources" and must explain any gap they identify.

Under the new framework, a PI at a smaller institution who is rated "Appropriate" on Factor 3 no longer carries a numeric Investigator and Environment disadvantage into the discussion.

What didn't change, and won't, is the Introduction page requirement for resubmissions. NIH gives you exactly one page to address every critique in your summary statement before the research plan begins. Some investigators use that page to relitigate their scientific position with reviewers. That doesn't work. The Introduction must acknowledge each specific concern directly, state what you changed in response, and point reviewers to the specific pages where they'll see those changes. Reviewers aren't looking for a defense; they're looking for evidence that you listened.

The honest problem with most summary statements is that applicants don't read them carefully enough to identify the signal versus the noise. Reviewers sometimes write extensive critiques on minor points because those are easier to articulate, while their actual reason for a poor score appears in a single sentence buried in the overall narrative. Researchers can spend months revising their methodology in response to detailed Approach critiques, only to get a worse score on resubmission because the core concern was a one-sentence comment about significance that they didn't address. Read the overall narrative first. That paragraph, not the criterion subcategories, tells you what the reviewer actually thought.


What NIH's Review Guidelines Doesn't Tell You About NIH Summary Statements

The overall impact score isn't a simple average of criterion scores. Study section members vote on overall impact independently, and a reviewer might give you a 2 on Factor 1 (Importance of the Research) but a 4 on overall impact. Read the discussion notes in context; the individual criterion scores tell you what to fix, but the overall impact score tells you what reviewers actually thought about the whole package.

Resume and resubmission applications get compared to the original. Reviewers have your A0 summary statement in front of them and will check whether you actually addressed each critique. Generic responses like 'we have revised the approach' without specifics almost always result in the same or worse score.

Unscored applications (those that were triaged) still have written critiques, but they're briefer. The key signal in a triaged application is which reviewer was assigned as primary versus secondary. The primary reviewer's comments carry the most weight because they set the tone during the discussion that determines whether you get discussed at all.

How to Read the Critiques in a Summary Statement

Most applicants fundamentally misread their summary statements. Here's what the document actually tells you versus what people think it says.

The individual criterion scores are less important than the comments underneath them. Applicants can obsess over getting a 2 versus a 3 on Factor 1 (or "Significance" on older-format mechanisms) when the real information is in the paragraph below. A reviewer who scores it a 3 but writes "the clinical impact is clear, though the team could strengthen the public health framing" is telling you something fixable. A reviewer who scores it a 2 but writes only a single vague sentence didn't engage deeply with your aims. The length and specificity of the critique tells you more about your resubmission prospects than the number itself. Detailed critiques give a resubmission something concrete to fix; vague critiques often don't.

An outlier score from one reviewer is worth reading closely. Assigned reviewers don't all share your subfield, and one may be judging whether your significance extends beyond it. When one reviewer gives you a 5 on Factor 1 while the other two gave you 2s, it can mean your application didn't communicate clearly to a non-specialist. This is an Aims page problem, not a science problem. Rewriting only the Specific Aims to be accessible to a broader audience can move a score substantially.

"Not discussed" is not a death sentence. It's data. Under NOT-OD-26-114, most 2026 meetings discuss only 30-35% of applications, and the "competitive but not discussed" middle third is still considered for funding. But the written critiques from triaged applications contain the roadmap for your resubmission. Applications triaged on first submission can score well on resubmission when the investigators take the critiques seriously. A useful step: call your program officer to discuss the summary statement before revising.


Sources


FAQ: Common Questions

When will I receive my NIH summary statement?

Some weeks after your study section meeting; NIH doesn't publish a fixed window. Study section meetings happen roughly 4 to 5 months after your submission deadline. You'll receive an automated notification from eRA Commons when the summary statement is available.

What does it mean if my NIH application was not discussed?

Not discussed (triaged) means your application wasn't brought to the full study section panel for scoring. Under NOT-OD-26-114, most meetings through the January 2027 council discuss only 30-35% of applications. Not-discussed applications are labeled either "competitive but not discussed" (still considered for funding) or "not competitive and not discussed." You'll still receive written critiques from the three assigned reviewers, but you won't receive an overall impact score or percentile rank.

What is the difference between a priority score and a percentile rank?

The priority score is a number from 10 to 90 reflecting the reviewers' assessment of your application's impact potential (lower is better). The percentile rank is where that score falls relative to all applications reviewed by the same study section over the past year. Institutes use the percentile rank, not the priority score, to set paylines, because it controls for variation in scoring stringency across different study sections.

How do I access my NIH summary statement?

Log into eRA Commons at era.nih.gov, work through to the "Status" section for your application, and look for the link to the summary statement in the status information. If you don't see it several weeks after the study section meeting, contact your eRA Commons help desk or the Scientific Review Officer listed on your summary statement.

Should I contact my program officer after receiving my summary statement?

Yes. Program officers can tell you things the summary statement can't: current payline, whether a resubmission is worth pursuing in the current funding climate, and qualitative context about your application's relative competitiveness. The call is brief (15 to 20 minutes) and low-stakes. Don't skip it.

G

Published by

Grantsights

Grantsights editorial content is reviewed against current program pages, award lists, notices, regulations, and application guidance before publication.

Source review

Each guide names the primary sources used for its program. Status, deadlines, eligibility, application routes, and award figures are checked against the source that owns that fact before publication. The page identifies its review date and separates current rules from historical planning evidence.

  • Primary sources selected from the agency, notice, regulation, or award system that owns each claim
  • Status, deadline, eligibility, and award figures rechecked at the page's displayed source-review date

Editorial accountability

Erik Jia, Founder and Editorial Lead

Accountable for source standards, corrections, product claims, and data-source transparency.

Source trust

How this guide is reviewed

Each guide is checked against the official notice, agency pages, and federal award records, and it's dated when those facts change.

Last updated: October 9, 2026. This page is reviewed regularly and updated when eligibility requirements, deadlines, or funding amounts change.

Get deadline alerts for grants like these

Enter your email for a weekly email of upcoming grant deadlines. When this guide has a current verified report, the confirmation email links to its free sample. Available reports are $49 each.

No spam. A weekly email with upcoming grant deadlines.